|
ATXN1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.93844940099552E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.67497135553185E-12 |
| Normal-vs-Stage2 |
8.32559999830451E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
4.66293670342566E-15 |
| Stage1-vs-Stage2 |
2.245200E-01 |
| Stage1-vs-Stage3 |
4.281600E-02 |
| Stage1-vs-Stage4 |
1.862450E-02 |
| Stage2-vs-Stage3 |
1.991660E-02 |
| Stage2-vs-Stage4 |
7.500000E-03 |
| Stage3-vs-Stage4 |
4.791800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.79756209917059E-12 |
| Normal-vs-AfricanAmerican |
2.47139999998147E-06 |
| Normal-vs-Asian |
2.19213536212237E-12 |
| Caucasian-vs-AfricanAmerican |
3.371200E-01 |
| Caucasian-vs-Asian |
7.460000E-01 |
| AfricanAmerican-vs-Asian |
2.596800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.71151981476214E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.721400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.73028258387831E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.68387526144897E-12 |
| Normal-vs-Age(81-100Yrs) |
3.572900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.974200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.761170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.142000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.800600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.988600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.884400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.158700E-04 |
| Classical-VS-Follicular |
8.143800E-01 |
| Classical-VS-Other |
1.515030E-01 |
| Classical-VS-Normal |
8.34521340919991E-12 |
| Tall-VS-Follicular |
5.123800E-03 |
| Tall-VS-Other |
9.918000E-01 |
| Tall-VS-Normal |
3.88578058618805E-15 |
| Follicular-VS-Other |
2.305800E-01 |
| Follicular-VS-Normal |
4.35629310402419E-12 |
| Other-VS-Normal |
6.22040000000101E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
4.57411886145564E-14 |
| N0-vs-N1 |
4.190000E-02 |
|
|
